glp-1 and multiple sclerosis Top Agonists Balance Weight Loss Efficacy, Safety From metabolism to mind: The

Declining estrogen shifts fat storage from subcutaneous depots to visceral ones, raises fasting insulin, and increases cardiovascular risk independent of caloric intake [1]

Pancreatitis risk has been reported with GLP-1 receptor agonists, though causality remains uncertain

BMI 25 to 30 (overweight) People starting in the overweight range can expect moderate but meaningful weight loss

While the complete results of the study have not yet been published, an initial press release in 2024 indicated that tirzepatide reduced the relative risk for the composite endpoint (HF urgent visit or hospitalization, oral diuretic intensification, or cardiovascular death) by 38%